EP3461474

GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Application Number
EP18201769A
Filing Date
Aug 31, 2011
Status
Revoked
May 27, 2022
Grant Date
Nov 11, 2020
External Links
Slate, Register

Biblio Summary

The patent EP3461474B1 was granted on Nov 11, 2020 by Glaxosmithkline Intellectual Property Development Limited The patent is currently Revoked.

The table below shows 4 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKAug 11, 2021ADMISSIBLE
HGF LIMITEDAug 9, 2021ADMISSIBLE
TEVAJul 13, 2021ADMISSIBLE
SANDOZJun 25, 2021ADMISSIBLE

The table below shows the patents of Glaxosmithkline Intellectual Property Development Limited that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3650019Fluticasone Furoate In The Treatment Of CopdOct 11, 20233
EP3297605Topical Pharmaceutical CompositionsMay 4, 20221
EP3481838Novel Processes For The Production Of OligonucleotidesAug 19, 20202